Endocrinology Vol. 142, No. 10 4469-4478
Copyright © 2001 by The Endocrine Society
Experimental IGF-I Receptor Deficiency Generates a Sexually Dimorphic Pattern of Organ-Specific Growth Deficits in Mice, Affecting Fat Tissue in Particular
Martin Holzenberger1,
Ghislaine Hamard,
Randa Zaoui,
Patricia Leneuve,
Bertrand Ducos,
Caroline Beccavin,
Laurence Périn and
Yves Le Bouc
INSERM, U-515, Hôpital Saint-Antoine (M.H., R.Z., P.L.,
B.D., C.B., L.P., Y.L.B.), 75571 Paris, France; and INSERM,
U-380, Faculté de Médecine Cochin-Port Royal
(G.H.), 75014 Paris, France
Address all correspondence and requests for reprints to: Dr. Martin Holzenberger, INSERM, U-515, Hôpital Saint Antoine, 75571 Paris Cedex 12, France. E-mail: holzenberger{at}st-antoine.inserm.fr
 |
Abstract
|
|---|
Reduced IGF type I receptor levels diminish postnatal growth rate
and adult body weight in mice. Here, we studied the impact of
experimental IGF receptor deficiency on tissue-specific growth by
Cre-lox-mediated dosage of a floxed
IGF-IR gene. We generated mice with a wide spectrum of receptor
deficiency (582%), and separated them into two groups with either
strong (
50%) IGF-IR deficiency (XS mice) or moderate deficiency
(<50%, M mice). The growth of XS mice was significantly retarded from
3 wk after birth onward, with respect to M littermates. This
effect was twice as strong in males as in females. Growth deficits
persisted throughout adult life, and at 1012 months, most organs and
tissues showed specific weight defects. Skin, bone and connective
tissue, muscle, spleen, heart, lung, and brain were the most severely
affected organs in the XS males. With the exception of muscle and
spleen, the same tissues were also significantly reduced in size in
females, although to a lesser extent. The most severe growth defect,
however, concerned adipose tissue. Fat pad size in XS males was
only 29% (females, 44%) of M mice. The estimated number of adipocytes
in XS male fat pads was only 21% that of M males (XS
female, 27%). Lipid content per cell was significantly higher in XS
adipocytes, whereas plasma glucose and insulin levels were low in
XS males. Thus, IGF type I receptor deficiency produced mice with
disproportionate postnatal organ growth, and these effects depended
strongly on sex. A marked reduction in IGF-IR levels resulted in a
major defect in adipose tissue.
 |
Introduction
|
|---|
IGFs ARE IMPORTANT regulators of embryonic
and postnatal growth in vertebrates. IGF-II is involved principally in
embryonic growth (1), whereas its homolog, IGF-I, is
involved in embryonic and postnatal growth (2). Both
ligands signal via the same tyrosine kinase receptor (IGF-IR) (3, 4). IGF-I and IGF-IR are essential mediators of GH activity in
the juvenile animal, and are still present at significant levels in
many tissues in the adult. Current efforts try to elucidate the
tissue-specific roles of IGF signaling in vivo, using
conditional genetic approaches (5, 6, 7). We applied
Cre-lox technology (8, 9, 10) to the IGF-IR gene
to identify major IGF target cells and organs and to dissect the
receptor function systematically (11).
Studies of the classical IGF-IR knockout (KO) suggested that during
embryonic development, lung, muscle and skin depend more strongly on
IGFs than other organs (12, 13). However, as classical
IGF-IR KO mice invariably die at birth, it has been difficult to extend
such studies to postnatal growth and development. The classical KO of
IGF-I produces a less severe developmental retardation, and depending
on genetic background, the complete, constitutive loss of IGF-I
function is not necessarily lethal (14, 15, 16, 17). This model is
of particular interest because some of the IGF signaling is maintained
during embryonic development through the action of IGF-II, such that
these mice become gradually IGF deficient toward the end of embryonic
development and the beginning of postnatal life, when endogenous IGF-II
is down-regulated. Interestingly, in juvenile
IGF-I-/- mice, the growth of lung tissue is
affected more than that of liver and kidney (17). From
these and other findings, it was deduced that musculo-skeletal
compartments may be major targets for postnatal action of IGF-I.
However, it is a complex task to assess the tissue-specific role of
IGFs, because these growth factors act via both paracrine and endocrine
mechanisms. It was shown that tissue-specific overproduction of IGF-I
in transgenic animals increases local growth (18, 19, 20). In
addition, liver-specific IGF-I gene KO in mice (6) showed
that most, if not all, postnatal and pubertal IGF-I-mediated growth can
be achieved through tissue-derived (nonhepatic) IGF-I as the
predominant postnatal source of IGF-I. The continuation of this and
other work, in particular the use of tissue-specific gain and loss of
function models, may show in the future which of the many cell
type-specific effects of IGFs identified in in vitro studies
are relevant in vivo.
By gene targeting we previously produced a hypomorphic IGF-I receptor
allele (a so-called knockdown, with partially reduced expression of
IGF-IR) and showed that reduced availability of the IGF-I receptor
slows down postnatal growth (21). The pubertal growth
spurt in these mice is smaller than that in normal mice and resulted in
a durable growth defect despite IGF-I up-regulation and IGF-binding
protein-4 (IGFBP-4) down-regulation. This hypomorphic gene mutation
affected total body weight more than the weight of individual organs
(e.g. thoracic organs, brain, or bone). We concluded that
other body compartments not evaluated in that study, such as skin or
muscle, would probably show more potent effects in response to IGF-I
receptor deficiency. To identify these compartments, we here produced a
mouse model with strongly and ubiquitously impaired IGF type I receptor
function, employing a gene dosage strategy (22, 23). We
also generated a Cre transgenic mouse that produces a useful
pattern of mosaic-early
embryonic-ubiquitous gene deletion (MeuCre). By
crossing this line with mice harboring the floxed hypomorphic IGF-IR
allele, we were able to generate mice with very low IGF-I receptor
levels. Under these conditions, sexually dimorphic patterns of pubertal
growth retardation were observed, and tissues and organs with
significant growth deficits were identified.
 |
Materials and Methods
|
|---|
Animals
The MeuCre transgenic line was produced by standard
pronuclear injection (24). MeuCre uses a
tet-operon/cytomegalovirus-minimal promoter controlling
expression of the Cre cDNA (25). Probably due
to positional effects, the MeuCre transgenic line produces
Cre constitutively during a short period of early embryonic
development. This early embryonic Cre expression results in
mosaic Cre-lox recombination, deleting, on the average, 40%
of the floxed alleles. MeuCre-mediated recombination
efficiency differs little between tissues in a given individual (see
Table 1
), indicating that it occurs
largely before organogenesis. Later, this recombination pattern is
transmitted to all developing tissues. We found that recombination
efficiency differs considerably between animals; the average
Cre recombination efficiency measured in tail DNA (n =
24) is 39.9 ± 21.5% (±SD; range,
6.385%). This interindividual variability increases the chances for
producing a large spectrum of degrees of gene expression deficiency in
the chosen experimental setup. MeuCre mice were mated with
IGF-IRneolox mice (21) to produce Cre-lox
double transgenics, which were then mated with homozygous IGF-IRneolox
mice to produce the F2 generation (Fig. 1
, A and B) (26).

View larger version (43K):
[in this window]
[in a new window]
|
Figure 1. Production of mice with various degrees of IGF-IR
deficiency. A, Targeted mutation: exon 3 (e3) of the WT IGF-IR gene was
replaced by a floxed exon 3 ( , loxP). A
neomycin resistance cassette (neo), equipped with a third
loxP site was cointroduced into intron 2. This created
the hypomorphic IGF-IRneolox allele. B, Breeding scheme for gene
dosage: MeuCre transgenic mice mated with IGF-IRneolox
mice produced double transgenic MeuCre/IGF-IRneolox
(F1). These were mated with homozygous IGF-IRneolox,
producing the F2 mice. These F2 mice comprised
six different genotypes that produced a large range of receptor
deficiency (indicated in percentage of WT). Using MeuCre and
IGF-IRneolox on C57BL/6 genetic background in F0 matings,
and homozygous IGF-IRneolox mice on 129/Sv background in F1
matings, we obtained C57BL/6129/Sv first generation hybrids in
F2. C, Representative F2 genomic Southern blots
for each genotype. In a HincII tail DNA digest, the WT
allele and the four possible forms of the targeted allele were detected
as discrete bands (see Materials and Methods for
details). MeuCre-mediated excision occurs at early
embryonic stages in all tissues, including germline cells. Thus, some
F2 mice received from their
MeuCre/IGF-IRneolox parent (B6) an IGF-IR KO allele. The
other allele was always inherited as IGF-IRneolox (NL) allele.
Different alleles produced different amounts of receptor compared to
WT: IGF-IRneolox, 60% (21 ); neo, 100%
(21 ) (a restored-to-WT mutation); ex3, 0%; and KO, 0%
(see Fig. 2 ). 129, Genetic background 129/SvPas; B6, C57BL/6
background; HcII, HincII site; MWM, DNA
mol wt marker; MeuCre, presence (+) or absence (-) of
MeuCre; neo, neomycin resistance cassette.
|
|
Mice were housed in standard conditions (25 C; 12-h light, 12-h dark
cycle; standard rodent diet containing 5% lipids and water ad
libitum). Pups were weaned at 25 d. All animal experiments
were conducted in accordance with the institutional guidelines for the
care and use of animals. Body weight was measured ±0.1 g at 3, 6, and
9 wk. Blood samples (100200 µl) were taken from adults by
retroorbital puncture using Pasteur pipettes rinsed with 0.5
M EDTA and by cardiac puncture at the time of
dissection. Plasma samples were stored at -20 C. We randomly selected
92 mice from the total of 126 F2 mice. These mice represented all 6
possible genotypes from both sexes and were killed before dissection at
1012 months of age. The wet weight of organs and tissues was
determined on a calibrated balance (e = 0.1 mg; Denver
Instruments, Arvada, CO). Data were handled using Excel
(Microsoft Corp., Redmond, WA) and analyzed with StatView
(Abacus Concepts, Inc., Berkeley, CA).
Details of the anatomical dissection
The skin was removed, with the exception of the tail tip and
feet. The brain was separated from spinal cord and removed. Limb
muscles were sectioned at their proximal insertions, limbs were removed
at their proximal joints, and feet were removed (bones accounted for
about 5% of limb weight; the rest was muscle). The genital fat pad,
also termed the inguinal or abdominal fat pad, and the major abdominal
and thoracic organs were prepared. Blood vessels were sectioned at the
organ hilus (kidney and liver). The large blood vessels of the heart
were cut at the atrium, and coagulated blood was removed from the
ventricles. The weight of the rest (difference between body
weight before death and the sum of the weights of the organs and
tissues) corresponded essentially to the gastrointestinal tract,
bladder, female reproductive organs, and uncollected blood. Feet and
any connective tissue removed during the dissection were added to the
carcass, which comprised essentially the skeleton and connective tissue
from the body and the head.
DNA preparation
DNA was prepared using standard procedures (27).
Tail biopsy samples (5 mm) from 10-d-old animals or tissue samples (50
mg; fat tissue, 200 mg) from adult animals were digested overnight with
proteinase K (Eurobio, Les Ulis, France) and centrifuged, and the
supernatant was mixed with an equal volume of isopropanol. The
resulting precipitate was washed with 75% ethanol, dried, and
resuspended in 10 mmol Tris, pH 8.0. For quantitative purposes,
deoxyribonuclease-free ribonuclease (Roche Molecular Biochemicals, Basel, Switzerland) was added, and
phenol/chloroform extractions were performed before precipitation. The
amount of DNA extracted from weighed, representative tissue fractions
was determined by UV spectrophotometry (Genesys 5, Spectronic
Instruments, Rochester, NY), and expressed in microgram per µl. Two
DNA extractions were performed per animal, and ODs were determined
twice per extraction.
To calculate cell size from DNA content we estimated the mouse genome
to 3.5 Gbp, so that 1 µg double stranded purified DNA corresponded to
2.6 x 105 extracted cell nuclei. The
specific weight (
) of tissues was estimated to be 1 mg/µl,
with the exception of that for adipose tissue, which was estimated to
be 0.8 mg/µl. The average cell volume (V) was calculated using V
(fl) = W (mg) x (
(mg/µl) x DNA (µg) x
2.6 x 105
(µg-1))-1, with W being
the weight of the extracted tissue fraction. To quantitatively evaluate
the individual fat cell compartment, the number of adipocytes was
estimated dividing the adipose tissue volume by the average adipocyte
volume.
Southern and dot blotting
DNA (8 µg) from each mouse was digested with
HincII, subjected to electrophoresis in a 1% agarose gel,
transferred to nylon membranes (Hybond+,
Amersham Pharmacia Biotech, Little Chalfont, UK) by
capillary action, and hybridized with a genomic probe (radiolabeled
using Rediprime, Amersham Pharmacia Biotech). The probe
recognized the 750-bp intronic region directly upstream from the
inserted neomycin resistance cassette. We detected a 2.4-kb wild-type
IGF-IR genomic fragment, a 4.5-kb targeted allele with floxed
neo-cassette and exon 3 (neolox (NL)), a 3.6-kb exon
3-excised (
ex3) allele, a 2.5-kb neo-cassette excised
(
neo) allele, and a 1.7-kb total excision (KO) allele. The size of
the loxP insertions (4050 bp) must be added to the
fragment sizes indicated in Fig. 1
. Membranes were placed against x-ray
film (Curix RP-2, Agfa-Gevaert, Mortsel, Belgium) for 14 d at -80 C
with amplifying screens. To quantify individual receptor deficiency
from genomic data, blots were exposed to phosphorimager screens and
analyzed using a STORM 850 PhosphorImager (Molecular Dynamics, Inc., Sunnyvale, CA) and ImageQuant. For dot-blotting, DNA (10
µg) was denatured by heating, transferred to nylon membranes, and
probed with 1.1 kb Cre cDNA.
Receptor binding assays
Recombinant human IGF-I (rhIGF-I; GroPep Pty. Ltd.,
Adelaide, Australia) was labeled with 125I
(Amersham Pharmacia Biotech) using the chloramine-T method
(SA,
100 µCi/µg). All chemicals were obtained from
Sigma (St. Louis, MO). Crude membranes were prepared from
whole brain as previously described (28). After
decapitation, brains were quickly removed and homogenized. The
homogenate was centrifuged twice at 4 C. The pellet was resuspended,
and the suspension was immediately used for binding assays. Proteins
were measured using the bicinchoninic acid protein assay from
Pierce Chemical Co. (Rockford, IL). Binding assays were
performed as previously described (21) in 0.5 ml 50
mM Tris-HCl buffer containing the membrane preparation (300
µg protein) and 1520 pM
[125I]rhIGF-I. Nonspecific binding was
determined in the presence of 200 nM rhIGF-I.
IGF-I assay
Plasma samples (1025 µl) were incubated in 0.01
M HCl for 30 min at room temperature and subjected to
ultrafiltration through Centricon 30 columns (Amicon, Millipore Corp., Bedford, MA). The ultrafiltrate was lyophilized,
resuspended in 0.1 M phosphate buffer and 1 mg/ml BSA, pH
7.4, and incubated for 3 d with
[125I]rhIGF-I (3000 cpm/tube) and a polyclonal
antihuman IGF-I antibody (final dilution, 1:120,000; a gift from J.
Closset, CHU, Liège, Belgium), that cross-reacts with
murine IGF-I (29, 30). Samples were tested at four
concentrations, each in duplicate (30). After incubation,
free and bound IGFs were separated using albumin-coated charcoal as
previously described (31). The detection threshold of the
assay was 2 ng/ml plasma. There was 5% intraassay variation and 10%
interassay variation.
Western ligand blotting of IGFBPs
Plasma samples (3 µl/animal) were subjected to 12.5%
nonreducing PAGE (32). Proteins were electrotransferred
onto nitrocellulose membranes and incubated with
[125I]IGF-I and
[125I]IGF-II (500,000 cpm each). Membranes were
washed and placed against x-ray film (Agfa-Gevaert) at -80 C. Pooled
normal samples of human and mouse origin were included on each gel as
standards. Western ligand blots were quantified using phosphorimager
technology and ImageQuant software (Molecular Dynamics, Inc.). Individual results were compared with standard mouse
samples on the same blot and normalized. Numerical results on
circulating levels of IGFBP-1 to -4 were statistically evaluated using
the Mann-Whitney test.
Histology and blood biochemistry
Genital fat pads from males and females were quickly frozen over
liquid nitrogen and embedded in Cryo-M-Bed (Bright, Huntingdon, UK).
Cryosections (-30 C, 15 µm) were prepared on SuperFrost Plus slides
(Menzel-Gläser, Braunschweig, Germany), fixed in 4%
paraformaldehyde for 20 min at 4 C, and stained with hematoxylin for 10
min. Blood biochemistry analysis was performed on a
Hitachi 911 using kits from Roche
(Indianapolis, IN; creatinine, cholesterol, triglycerides, and urea)
and Randox (Crumlin, UK; glucose, proteins) and protocols adapted to
the small volumes of plasma available from mice. Plasma insulin was
determined using the INSIK5 kit (DiaSorin, Inc.,
Stillwater, MN).
 |
Results
|
|---|
Production of a mouse population with various degrees of IGF-IR
deficiency
We have previously generated a Cre transgenic mouse
that produced mosaic-early embryonic
ubiquitous Cre-Lox recombination
(MeuCre) (Table 1
). In the early embryo, this line
constitutively produced mosaic Cre-mediated recombination
patterns very useful for a gene dosage approach (details in
Materials and Methods). We crossed this
MeuCre line with mice carrying the hypomorphic IGF-IRneolox
allele (Fig. 1A
) (21) following the strategy shown in Fig. 1B
. As MeuCre also generated mosaicism among germline cells
of the F1 double transgenics (with the same
efficiency as in other tissues), F2 mice
inherited various combinations of IGF-IRneolox, wild-type (WT), and
complete KO alleles with or without the MeuCre transgene.
This produced a wide spectrum of mutant genotypes in the
F2 generation (Fig. 1C
). To make it possible to
deduce the degree of receptor deficiency directly from these genotypes,
we measured IGF type I receptor levels in groups of mice with various
allelic combinations by receptor-ligand binding assay (Fig. 2
). The IGF-IRneolox allele produced 40%
less receptor than the WT. No receptors were produced from the complete
KO allele, and heterozygous KO mice had about half the number of
receptors present in normal mice. Various combinations of alleles
confirmed that these mutations were essentially not compensated by the
sister allele, and that their effects were therefore additive. Thus,
the combination of the IGF-IRneolox and IGF-IR KO alleles resulted in
70% receptor deficiency. If such mice had also inherited a
MeuCre-transgene, then more than 80% IGF-IR deficiency was
possible through additional somatic Cre recombination. As
MeuCre is expressed during the early embryonic stages, these
acquired receptor deficiencies were considered constitutive for the
individual. The degree of IGF receptor deficiency was then determined
for all 126 F2 mice directly from their
individual allele distributions using phosphorimager data from genomic
Southern blots and an appropriate algorithm. As expected, the combined
effects of hypomorphic IGF-IRneolox alleles, complete KO alleles, and
somatic Cre recombination produced an
F2 generation with a wide range of receptor
deficiency (Fig. 3A
). Two large groups of
mice, one that displayed moderate levels of deficiency (M) and one with
strong deficiency (XS), could be distinguished. Most of the M mice had
1030% receptor deficiency; most of the XS mice had 7080%
deficiency. XS mice had, on the average, three times fewer receptors
per cell than M mice. In this study XS mice were compared with M mice;
the latter served as the control group. Although some of the XS animals
had more than 80% receptor deficiency, none showed signs of the
classical IGF receptor KO phenotype (respiratory insufficiency and
neonatal death). Two of the 126 F2 mice died
before adulthood, but there was no indication that this was related to
their individual degree of receptor deficiency (21% and 45%,
respectively).

View larger version (29K):
[in this window]
[in a new window]
|
Figure 2. IGF-I receptor binding as a function of IGF-IR
genotype. We tested for the presence of functional IGF-IR in 35 mice
with various combinations of mutant alleles using an in
vitro receptor ligand binding assay (21 ). For this
assay we chose mice that did not harbor MeuCre. Mean
values for receptor binding in mice were from 278 fmol/µg total
protein in WT mice to undetectable (*) in the complete knockout mice.
As complete KO is lethal at birth, we analyzed whole
IGF-IR-/- embryos on embryonic d 19; in all other mice,
binding was measured in the adult brain tissue. Each IGF-IRneolox
allele (NL) reduced receptor binding per cell by 20%; each KO allele
reduced receptor binding by about 50%. If mutant alleles were
combined, the reduction of receptor levels was additive. We observed no
sex-related differences. Inset, IGF receptor binding in
preparations from whole embryonic d 19 embryos showed the average
receptor dosage in the embryo. This suggested that receptor dosage
occurred in the entire embryo and was not restricted to specific
(e.g. nervous) tissues.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
Figure 3. Receptor deficiency and postnatal growth of M and
XS mice in the F2. A, Genetically induced receptor
deficiency in the F2 ranged from 582%. Two large groups
were distinguished: 75 mice showing moderate receptor deficiency (M;
049%) and 51 mice showing stronger deficiency (XS; 50100%). We
analyzed the growth defects, comparing XS with M mice. B, Differences
in mean body weight were observed at 3, 6, and 9 wk between the M and
XS groups. Comparison with a WT cohort from an independent experiment
at 9 wk of age showed that the postnatal growth of M mice was slightly
impaired. Note that the differences between XS and M were significant
from 3 wk onward. Levels of significance for the differences between XS
and M: *, P < 0.05; **, P <
0.01; ***, P < 0.001 (by Mann-Whitney test).
Error bars indicate the SEM.
|
|
Effects of IGF-IR gene dosage on postnatal growth and IGF system
regulation
XS mice weighed significantly less than M littermates from 3 wk
after birth onward (Fig. 3B
). Relative weight differences were stable
throughout growth and into adulthood. At 1012 months, XS males were
78% the weight of M males, and XS females were 86% the weight of
their M littermates. The effect of IGF-IR gene dosage on male mice was
thus 1.8 times stronger than that on females. The mean plasma IGF-I
concentration in the M group (491 ± 28 ng/ml) was normal and
similar to that in the WT (490 ± 34 ng/ml); XS mice tended to
have lower plasma IGF-I levels (-8%). Plasma levels of IGFBP-1, -2,
-3, and -4 were lower than those of M mice; this difference was
statistically significant for IGFBP-2 (-21%) and IGFBP-4 (-22%;
Table 2
). One has to bear in mind,
however, that Western ligand blotting is a semiquantitative method.
View this table:
[in this window]
[in a new window]
|
Table 2. Mean plasma concentrations of IGF-I (RIA) and
IGFBP-1 to IGFBP-4 (Western ligand blotting, WLB) in M and XS males
|
|
M mice grew slightly less well than wild-type 129/Sv mice raised under
the same conditions, and the full effect of IGF-IR gene dosage on
tissue-specific growth (see below) would probably have appeared even
stronger if XS mice had been compared with a corresponding WT control
population. However, we preferred to compare XS directly with M mice,
because both groups were issued from the same matings and therefore
were a homogeneous population with respect to genetic background,
growth cohort, litter size, etc., factors known to affect
pre- and postnatal growth and development in mice.
Tissue-specific growth deficits
We dissected 92 of the M and XS mice and found that organs and
tissues were affected differently by decreased IGF-IR levels (Table 3
). We studied all major body
compartments and found that bone together with connective tissue (the
carcass) and skin were among the most strongly affected tissues. Lung,
heart, spleen, and brain were also much reduced in size. The muscle
compartment was affected in males, but was less affected in females.
Thymus, kidney, and liver were less affected in both sexes (Fig. 4
). For all of these organs and tissues,
the weight reduction in XS mice was concordant in both sexes, but more
pronounced in males than in females. The correlation between male and
female tissue-specific weight deficits was r2 =
0.30 (P < 0.05) without fat tissue and
r2 = 0.91 (P < 0.0001) with fat
tissue. We are sure that this result was not due to potential
tissue-specific effects of the MeuCre transgene, because we
obtained very similar results in F2 mice when all
35 MeuCre-positive individuals were excluded from the 92
dissected animals (results not shown). When we analyzed organ weight
relative to body weight, liver and kidney weights increased
significantly relative to body weight, whereas the relative weight of
fat tissue showed a highly significant decrease in XS mice.
View this table:
[in this window]
[in a new window]
|
Table 3. Tissue-specific weight differences in adult mice
with strong (XS) and moderate (M) IGF-I receptor deficiency
|
|

View larger version (28K):
[in this window]
[in a new window]
|
Figure 4. Effects of IGF-IR gene dosage on organ-specific
weight in adult males and females. The mean wet weight of organs and
tissues from XS mice was expressed in percent of the M group and
plotted on the y-axis (see Table 3 for numerical data).
Results from males (left side) were compared with those
from females (right side). Dark shading
of boxes indicates that the observed XS/M difference was statistically
significant. Error bars (drawn unilaterally for clarity)
indicate the SEM. Connecting lines between
male and female ratios are drawn in dark gray for those
tissues with a sex-linked difference greater than 5%. The proportion
of mean total body weight (weight) is indicated by framed
boxes. Skin, carcass, spleen, heart, muscle (males only),
brain, and lung showed large weight deficits in XS mice. Adipose tissue
was the most sensitive tissue to receptor deficiency in both sexes.
|
|
During early embryogenesis, MeuCre-positive
F2 mice produced mosaic tissues composed of cells
with various degrees of receptor deficiency. In M mosaics, individual
cells showed either 20% (NL) or 50% (heterozygous KO) receptor
deficiency. In XS mosaics (i.e. mice with one floxed allele,
one KO allele, and MeuCre), individual cells showed either
70% (NL plus KO allele) or 100% (two KO alleles) receptor deficiency.
Southern analysis (Fig. 5
) showed that in
M mosaics, many 50% receptor-deficient cells were present in adult
tissues together with cells with 20% deficiency. In the adult XS
mosaics, however, total KO cells were scarce, suggesting that these
cells contributed less to the growth of the tissues and/or that they
were less efficiently maintained during growth or afterwards, in the
adult tissues. We think that the relative underrepresentation of XS
mice with 8090% reduction in receptor binding in Fig. 3A
could also
be explained by this in vivo cell selection effect.

View larger version (57K):
[in this window]
[in a new window]
|
Figure 5. Cells with a complete loss of both IGF receptor
alleles are underrepresented in XS mice. Using DNA extracted from tail
biopsy and Southern blotting, a selection of
MeuCre-positive mice with the IGF-IRneolox/WT (M) or
IGF-IRneolox/KO (XS) genotype were compared. The 3.6-kb band indicates
the presence of the ex3 allele, which is functionally equivalent to
the total KO allele. This allele was present in a significant
percentage of cells in tail biopsy samples from M mice
(left), but was undetectable in samples from XS mice
(right side of the panel). In M cells, the second allele
was always WT, whereas in XS cells, it was always KO.
|
|
We investigated whether organ-specific growth deficits were caused by
hypoplasia or hypotrophy by estimating mean cell size using
quantitative DNA extraction from tissues. No tissue other than fat
tissue (see below) showed significant changes in DNA content per cell
(data not shown). We concluded that hypoplasia, rather than hypotrophy,
was responsible for low organ weight in muscle, heart, liver, kidney,
brain, spleen, and thymus.
Lack of white adipose tissue in IGF-IR insufficiency
Little fat tissue was present in XS mice. The genital fat pad
weighed less than 30% in XS males and less than 45% in XS females
compared with that in M mice. The data for individual mice (Fig. 6A
) showed that the mass of the fat pad
was distributed very differently in the M and XS populations. The fat
pads of M mice showed a large range of sizes (0.16 g), with most
between 0.12 g; the XS mice generally had fat pads weighing less than
1 g, and large fad pads were absent. To estimate cell volume and
density in genital fat pads, we extracted adipocyte DNA from M and XS
mice. In both sexes, there was significantly less DNA per unit wet
weight of adipose tissue from XS mice than from M mice (Table 4
), indicating that cell volume was
larger in XS than in M fat pads. Similar results were obtained even if
all individuals with more than 1.3 g adipose tissue were removed
from the analysis, so that fad pads of approximately the same size but
with different degrees of receptor deficiency were compared.
View this table:
[in this window]
[in a new window]
|
Table 4. Mean cell volume1
in fat tissue (in femtoliter ± SEM) comparing adult
males and females with strong (XS) and moderate (M) IGF-I receptor
deficiency (b P <
0.05; Mann-Whitney test)
|
|
Thus, two parameters, mean cell volume and weight of fat pad, clearly
distinguished XS and M adipose tissue (Fig. 6B
). Although the volume of
fat cells was significantly greater in XS mice, these mice appeared to
be unable to build up larger fat depots. We estimated the number of
adipocytes in fat pads of XS males to be 56 x
109 (± 13 x 109)
cells, which corresponds to only 21.3% of the mean value for M mice
(27.1% for XS females). These figures are probably still an
overestimate, because DNA extraction did not differentiate between
adipocytes and other cell types present in fat tissue (e.g.
blood vessels or connective tissue). Histology confirmed that XS fat
tissue was composed of large adipocytes (Fig. 7
, AF) and contained very few cell
nuclei and large vacuole-like spaces. M adipocytes varied in size,
whereas XS fat tissue seemed to be mostly composed of uniformly large
adipocytes. We compared tail and fat tissue genotypes in
MeuCre-positive F2 mice. Mosaic
patterns induced by MeuCre in fat tissue did not differ
significantly from that in the tail (an example is shown in Fig. 7G
),
suggesting that fat tissue-specific MeuCre activity was not
different from MeuCre activity in other tissues. Fat tissue
also showed the same relative lack of complete KO cells as did other
tissues.
Serum creatinine, urea, total protein, cholesterol, and triglycerides
were not affected in XS mice. Blood glucose levels were normal in XS
females, but significantly lower in XS males (mean ±
SEM, 7.2 ± 0.6 in XS males vs. 9.7 ±
0.5 mmol/liter in M males; P < 0.01). Nonfasting
plasma insulin levels were within the normal range for the M males and
the M and XS females (25.7 ± 3.6 µIU/ml). In contrast, XS males
had significantly lower plasma insulin concentrations (16.6 ± 2.3
µIU/ml; P < 0.05).
 |
Discussion
|
|---|
The IGF-I receptor gene is biallelically expressed in mice.
Combinations of mutant receptor alleles (e.g. partial
deficiency of one allele with total deficiency of the second allele, or
partial deficiency of both alleles) had additive effects in terms of
the decrease in number of cell surface IGF-I receptors. This suggests
that IGF-I receptor deficiency does not induce significant allelic
regulation. This is consistent with the recent finding
(33) that classical IGF-IR KO mice display a growth
deficiency phenotype in the heterozygous state, but not with the
original finding of Liu et al. (12) that
heterozygous receptor KO mice show normal receptor expression and
normal growth. Clearly, the Cre-lox gene targeting used here
does not result in significant up-regulation of receptor production
even if the number of IGF-IR at the cell surface is only 2030% of WT
levels. It is unclear whether this is related to the structure of the
mature transcripts, which can be deduced for the various forms of
targeted alleles used here. The wild-type IGF-IR allele produces an
11-kb mRNA containing large 5'- and 3'-untranslated regions. The
IGF-IRneolox allele produces mature transcripts that contains, in 40%
of cases, short RNA insertions from the neo-cassette, which cause
receptor deficiency at the translational level (21). The
Cre-lox induced KO allele also produces an intact mRNA,
except that it lacks the 313-nucleotide region encoding exon 3. In this
case, receptor deficiency occurs at the translational level due to a
frameshift at the exon 2/exon 4 junction. IGF-IR thereby
ends with lysine183, is followed by a 27-amino acid
nonsense peptide, and is terminated by a new stop codon (nucleotides
8486 of mouse exon 4). In the conventional KO alleles, to the
contrary, the open reading frame of the IGF-IR gene had been
interrupted by an exonic neo-cassette insertion, leading to mRNAs
truncated at exon 3.
Adult XS mice with about one quarter the number of receptors present in
normal mice were viable and fertile. However, consistent with previous
findings (21), this level of receptor deficiency
significantly impaired the postnatal and, in particular, pubertal
growth of male and female mice. We conclude that two functional
receptor alleles are necessary for normal postnatal growth. The growth
retardation did accumulate during prepuberty and puberty. No
significant catch-up growth was observed in XS mice after puberty, as
it has been reported for the double IGF-IR/M6P-R(IGF-IIR)-KO mutant
(34). Male XS mice in this study reached 70% of WT
weight, and their growth retardation was therefore less severe than
that of classical IGF-I KO mice (
30% of adult WT weight)
(12). This suggests that in XS mice, the remaining
2030% receptors mediate more than half of the IGF-dependent
postnatal weight gain.
The sexual dimorphism of pubertal growth depends on the
IGF-IR
In XS mice with low functional IGF-IR levels, much of the normal
sex-related postnatal growth dimorphism had disappeared. Androgens and
estrogens are the most likely candidates for regulating sexually
dimorphic growth in puberty and postpuberty. However, direct evidence
implicating these hormones in body growth is scarce. GH secretion
patterns, on the other hand, are sexually dimorphic, showing solid
regular peaks and low intermediate levels in males and more frequent
peaks with higher intermediate levels in females (35).
However, it is not known in detail how these dimorphic secretion
patterns generate divergent growth in males and females. GH-dependent,
hepatic IGF-I production does not seem to be involved, because in a
number of mammalian species, circulating IGF-I levels are clearly not
correlated with sex-linked differences in somatic development
(36). As the IGF receptor seems to mediate at least part
of the additional growth of males (Ref. 21 and results
reported here), we believe that the causes of sexually dimorphic growth
differences are probably situated at the level of the target cell.
Local IGF-I production, which is known to have determining effects on
body growth (6), may be regulated by androgens and/or
estrogens, or androgens may cooperate with IGF signaling in target
tissues. This would result in higher levels of IGF signaling, regulated
on a paracrine/autocrine basis, with no change in the total circulating
IGF concentration.
In the IGF-IR knockdown model, the growth of males was more retarded
than that of females, whereas IGF-I was up-regulated, and IGFBP-4 was
down-regulated. As greater receptor deficiency was observed in the
present model than in the knockdown model, we expected the IGF-I
concentration to be high. Circulating IGF ligand levels were, however,
similar to or even lower than normal levels. As the IGF-I concentration
is high in fat tissue (37, 38), it is possible that the
significant lack of adipocytes in XS mice may have counteracted, to
some degree, any underlying physiological up-regulation of IGF-I. In
addition, IGFBP levels tended to be lower in XS mice, which also might
lower the circulating IGF-I concentration in the adult. Plasma
concentrations of IGFBP-2, IGFBP-3, and IGFBP-4 were significantly
correlated with IGF-I levels. Finally, the down-regulation of IGFBP-4,
here accompanied by a significant decrease in IGFBP-2, seems to be a
consistent trait in IGF type I receptor deficiency. As IGF-I and
IGFBP-3 levels are known to be normal in some human growth
retardations, it may be interesting to study IGFBP-4 in these
conditions.
Studies using transgenic mice suggested that IGFBP-4 is a functional
antagonist of IGF-I in vivo (39). The low
IGFBP-4 (and IGFBP-2) levels observed in our study could thus be a
regulatory response by which IGF-IR-deficient XS males try to increase
growth. Transgenic overexpression of IGF-I, although increasing IGFBP-5
production, did not alter IGFBP-4 levels (40). This
indicated that regulation of IGFBP-4 may not be secondary to changes in
circulating IGF-I levels (in the present study IGF-I levels of XS males
were not significantly altered), but could be more directly related to
reduced levels of IGF-IR (21). Clearly, further
experiments are needed to clarify some of these important points
concerning IGF system regulation.
Organ-specific effects of ubiquitous IGF-IR deficiency
We show here that receptor deficiency created a sexdimorphic
growth deficit that affected various tissues to different degrees. Body
compartments, such as bone and cartilage, muscle, and skin, which are
often not directly evaluated, showed the strongest effects. In
contrast, other organs, such as the heart, liver, and kidney, showed
relatively small effects. In XS males, there was only about one quarter
the normal amount of fat tissue, indicating a high sensitivity to IGF
receptor deficiency.
We found a significant correlation between male and female
tissue-specific growth deficits. In both sexes, tissues showed either a
strong growth deficit (adipose tissue, skin, heart, lung, bone,
cartilage and connective tissue, spleen, and brain) or a weak deficit
(kidney, thymus, and liver). Some tissues or organs, however, showed
sex-specific growth deficits (bone, cartilage and connective tissues,
spleen, muscle, and liver). These results were consistent with findings
for the classical IGF receptor KO, in which the principal neonatal
defects concerned skin, brain, skeleton, lung, and muscle
(12). Our observations are also consistent with results
from other studies (reviewed in Ref. 2), in that the
degree of organ and/or tissue growth retardation in IGF-IR-deficient
mice corresponds well to the magnitude of overgrowth in IGF-I
overproducing mice, indicating the tissues whose growth is especially
dependent on IGF signaling, such as heart, brain, skin, muscle,
cartilage, and bone. A particular advantage of the present model over
tissue-specific ligand overproduction, however, is that the genetically
fixed receptor deficiency allows comparison of the IGF sensitivities of
multiple tissues in a single experimental animal.
Adipose tissue
We observed a strong growth deficit in fat tissue. Interestingly,
fat tissue produces large amounts of IGF-I (even when compared with
synthesis in the liver). In addition, this IGF-I production is GH
dependent, and preadipocytes are sensitive to IGF-I signaling
(37). Moreover, preadipocytes produce significant amounts
of IGF-IR, whereas mature adipocytes do not (41). Our
findings are compatible with the idea that the IGF-I produced by fat
tissue may have major paracrine and autocrine functions during the
ontogenesis of fat tissue. Cell culture studies on the proliferation of
adipocyte precursor cells and their differentiation into mature
adipocytes have identified IGFs as important regulators of adipocyte
development (42, 43). Experiments using primary cultures
of adipocyte precursors have shown that IGFs increase the proliferation
of these precursors and inhibit terminal adipocyte differentiation
(44). A similar mechanism could explain the reduction in
size of the adipocyte compartment in XS mice, through limitation of
adipocyte precursor proliferation in vivo and stimulation of
differentiation into mature adipocytes.
Our findings are consistent with recent in vivo studies by
Rajkumar et al. (45), who investigated
adipogenesis in IGFBP-1-overproducing transgenic mice. No significant
difference in fat pad development was observed between
IGFBP-1-overproducing mice and WT mice fed a normal diet. However, if
the mice were fed a diet rich in glucose, IGFBP-1-overproducing mice
were less able than wild-type mice to increase their fat tissue. In
contrast to our findings, however, adipocytes in IGFBP-1-overproducing
mice were smaller than cells in wild-type mice. These researchers found
evidence that IGFBP-1-overproducing fat tissue is less able to generate
adipocyte colonies in primary culture. This is consistent with there
being a defect in preadipocyte proliferation and adipocyte
differentiation due to impaired IGF signaling. Complete insulin
receptor deficiency has also been found to affect the formation of
adipose tissue in mice (46), suggesting that insulin and
IGFs may finally both be involved in the control of fat tissue
development.
 |
Acknowledgments
|
|---|
We thank Hermann Bujard and Werner Müller for plasmids,
Dominique Daegelen for providing access to the microinjection
facilities at the Institut Cochin de Génétique
Moléculaire (Paris, France), Philippe Monget for critical reading
of the manuscript, and Julie Sappa for language revision. We are
indebted to Frédérique Veinberg for blood biochemistry
analysis.
 |
Footnotes
|
|---|
This work was supported by INSERM, Ministère de lEducation
Nationale, Recherche et Technologie, Association Française
contre les Myopathies, and the University of Paris VI
(Faculté de Médecine Saint Antoine).
1 Fellow of Novo Nordisk (France). 
Abbreviations: IGFBP, IGF-binding protein; IGF-IR, IGF type I
receptor; KO, knockout; M, moderate IGF type I receptor deficiency;
MeuCre, mosaic-early
embryonic-ubiquitous Cre transgene; NL,
neolox; rhIGF, recombinant human IGF-I; WT, wild-type; XS, strong
(
50%) IGF type I receptor deficiency.
Received May 10, 2001.
Accepted for publication July 3, 2001.
 |
References
|
|---|
-
De Chiara TM, Efstratiadis A, Robertson EJ 1990 A growth-deficiency phenotype in heterozygous mice carrying an
insulin-like growth factor II gene disrupted by targeting. Nature.
345:7880
-
DErcole AJ 1999 Actions of IGF system proteins
from studies of transgenic and gene knockout models. In: Rosenfeld R,
Roberts Jr C, eds. The IGF system. Totowa: Humana Press; 545577
-
Blakesley VA, Butler AA, Koval AP, Okubo Y, LeRoith
D 1999 IGF-I receptor function: transducing the IGF-I signal into
intracellular events. In: Rosenfeld R, Roberts Jr C, eds. The IGF
system. Totowa: Humana Press; 143164
-
Werner H 1999 Molecular biology of the type I IGF
receptor. In: Rosenfeld R, Roberts Jr C, eds. The IGF system. Totowa:
Humana Press; 6388
-
Liu JL, Grinberg A, Westphal H, et al. 1998 Insulin-like growth factor-I affects perinatal lethality and postnatal
development in a gene dosage-dependent manner: manipulation using the
Cre/loxP system in transgenic mice. Mol Endocrinol 12:14521462[Abstract/Free Full Text]
-
Yakar S, Liu JL, Stannard B, et al. 1999 Normal
growth and development in the absence of hepatic insulin-like growth
factor I. Proc Natl Acad Sci USA 96:73277329
-
Sjögren K, Liu JL, Blad K, et al. 1999 Liver-derived insulin-like growth factor I (IGF-I) is the principal
source of IGF-I in blood but is not required for postnatal body growth
in mice. Proc Natl Acad Sci USA 96:70887092[Abstract/Free Full Text]
-
Kühn R, Schwenk F, Aguet M, Rajewsky K 1995 Inducible gene targeting in mice. Science 269:14271429[Abstract/Free Full Text]
-
Marth JD 1996 Recent advances in gene mutagenesis
by site-directed recombination. J Clin Invest 97:19992002[Medline]
-
Müller U 1999 Ten years of gene targeting:
targeted mouse mutants, from vector design to phenotype analysis. Mech
Dev 82:321[CrossRef][Medline]
-
Holzenberger M, Hamard G, Leneuve P, et al. 1999 Partial invalidation and dosage of the IGF type 1 receptor gene via
homologous and Cre-lox recombination results in postnatal proportionate
dwarfism [Abstract]. Growth Hormone IGF Res 9:308309[Medline]
-
Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis
A 1993 Mice carrying null mutations of the genes encoding
insulin-like growth factor I (IGF-1) and type 1 IGF receptor (Igf1r).
Cell 75:5972[Medline]
-
Baker J, Liu J-P, Robertson EJ, Efstratiadis A 1993 Role of insulin-like growth factors in embryonic and postnatal growth.
Cell 75:7382[CrossRef][Medline]
-
Powell-Braxton L, Hollingshead P, Warburton C, et
al. 1993 IGF-I is required for normal embryonic growth in mice.
Genes Dev 7:26092617[Abstract/Free Full Text]
-
Powell-Braxton L, Hollingshead P, Giltinan D, Pitts-Meek
S, Stewart T 1993 Inactivation of the IGF-I gene in mice results
in perinatal lethality. Ann NY Acad Sci 692:300301[CrossRef][Medline]
-
Beck KD, Powell-Braxton L, Widmer HR, Valverde J, Hefti
F 1995 Igf1 gene disruption results in reduced brain
size, CNS hypomyelination, and loss of hippocampal granule and striatal
parvalbumin-containing neurons. Neuron 14:717730[CrossRef][Medline]
-
Wang J, Zhou J, Powell-Braxton L, Bondy C 1999 Effects of Igf1 gene deletion on postnatal growth patterns.
Endocrinology 140:33913394[Abstract/Free Full Text]
-
Carson MJ, Behringer RR, Brinster RL, McMorris FA 1993 Insulin-like growth factor I increases brain growth and central
nervous system myelination in transgenic mice. Neuron 10:729740[CrossRef][Medline]
-
Coleman ME, DeMayo F, Yin KC, et al. 1995 Myogenic
vector expression of insulin-like growth factor I stimulates muscle
cell differentiation and myofiber hypertrophy in transgenic mice.
J Biol Chem 270:1210912116[Abstract/Free Full Text]
-
Reiss K, Cheng W, Ferber A, et al. 1996 Overexpression of IGF-I in the heart is coupled with myocyte
proliferation in transgenic mice. Proc Natl Acad Sci USA 93:86308635[Abstract/Free Full Text]
-
Holzenberger M, Leneuve P, Hamard G, et al. 2000 A
targeted partial invalidation of the insulin-like growth factor I
receptor gene in mice causes a postnatal growth deficit. Endocrinology 141:25572566[Abstract/Free Full Text]
-
Nagy A, Moens C, Ivanyi E, et al. 1998 Dissecting
the role of N-myc in development using a single targeting vector to
generate a series of alleles. Curr Biol 8:661664[CrossRef][Medline]
-
Nagy A 2000 Cre recombinase: the universal reagent
for genome tailoring. Genesis 26:99109[CrossRef][Medline]
-
Hogan B, Beddington R, Constantini F, Lacy E 1994 Manipulating the mouse embryo, 2nd ed. Cold Spring Harbor: Cold Spring
Harbor Laboratory Press; 226247
-
Baron U, Freundlieb S, Gossen M, Bujard H 1995 Co-regulation of two gene activities by tetracycline via a
bidirectional promoter. Nucleic Acids Res 23:36053606[Free Full Text]
-
Dietrich P, Dragatsis I, Xuan S, Zeitlin S, Efstratiadis
A 2000 Conditional mutagenesis in mice with heat shock
promoter-driven cre transgenes. Mamm Genome 11:196205[CrossRef][Medline]
-
Hogan B, Beddington R, Constantini F, Lacy E 1994 Manipulating the mouse embryo, 2nd ed. Cold Spring Harbor: Cold Spring
Harbor Laboratory Press; 296298
-
Durieux C, Ruiz-Gayo M, Corringer PJ, Bergeron F, Ducos
B, Roques BP 1992 [3H]pBC 264, a suitable
probe for studying cholecystokinin-B receptors: binding characteristics
in rodent brains and comparison with [3H]SNF 8702. Mol Pharmacol 41:10891095[Abstract]
-
Gay E, Seurin D, Babajko S, Doublier S, Cazillis M,
Binoux M 1997 Liver-specific expression of human insulin-like
growth factor binding protein-1 in transgenic mice: repercussions on
reproduction, ante- and perinatal mortality and postnatal growth.
Endocrinology 138:29372947[Abstract/Free Full Text]
-
Bessone S, Vidal F, Le Bouc Y, Epelbaum J, Bluet-Pajot
MT, Darmon M 1999 EMK protein kinase-null mice: dwarfism and
hypofertility associated with alterations in the somatotrope and
prolactin pathways. Dev Biol 214:87101[CrossRef][Medline]
-
Binoux M, Seurin D, Lassarre C, Gourmelen M 1984 Preferential measurement of insulin-like growth factor (IGF) I-related
peptides in serum with the aid of IGF binding proteins (IGFBPs)
produced by rat liver in culture. Estimation of serum IGFBP levels.
J Clin Endocrinol Metab 59:453462[Abstract]
-
Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S,
Binoux M 1986 Analysis of serum insulin-like growth factor binding
proteins using western blotting: use of the method for titration of the
binding protein and competitive binding studies. Anal Biochem 154:138143[CrossRef][Medline]
-
Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL,
White MF 1999 Irs-2 coordinates Igf-1 receptor-mediated ß-cell
development and peripheral insulin signalling. Nat Genet 23:3239[Medline]
-
Ludwig T, Eggenschwiler J, Fisher P, DErcole AJ,
Davenport ML, Efstratiadis A 1996 Mouse mutants lacking the type 2
IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and
Igf1r null backgrounds. Dev Biol 177:517535[CrossRef][Medline]
-
Mauras N, Rogol AD, Haymond MW, Veldhuis JD 1996 Sex steroids, growth hormone, insulin-like growth factor-1:
neuroendocrine and metabolic regulation in puberty. Horm Res 45:7480[Medline]
-
Gatford KL, Egan AR, Clarke IJ, Owens PC 1998 Sexual dimorphism of the somatotrophic axis. J Endocrinol 157:373389[CrossRef][Medline]
-
Peter MA, Winterhalter KH, Boni-Schnetzler M, Froesch
ER, Zapf J 1993 Regulation of insulin-like growth factor-I (IGF-I)
and IGF-binding proteins by growth hormone in rat white adipose tissue.
Endocrinology 133:26242631[Abstract]
-
DErcole AJ, Stiles AD, Underwood LE 1984 Tissue
concentrations of somatomedin C: further evidence for multiple sites of
synthesis and paracrine or autocrine mechanisms of action. Proc Natl
Acad Sci USA 81:935939[Abstract/Free Full Text]
-
Wang J, Niu W, Witte DP, et al. 1998 Overexpression
of insulin-like growth factor-binding protein-4 (IGFBP-4) in smooth
muscle cells of transgenic mice through a smooth muscle
-actin-IGFBP-4 fusion gene induces smooth muscle hypoplasia.
Endocrinology 139:26052614[Abstract/Free Full Text]
-
Ye P, DErcole J 1998 Insulin-like growth factor I
(IGF-I) regulates IGF binding protein-5 gene expression in the brain.
Endocrinology 139:6571[Abstract/Free Full Text]
-
Smith PJ, Wise LS, Berkowitz R, Wan C, Rubin CS 1988 Insulin-like growth factor-I is an essential regulator of the
differentiation of 3T3L1 adipocytes. J Biol Chem 263:94029408[Abstract/Free Full Text]
-
Wabitsch M, Hauner H, Heinze E, Teller WM 1995 The
role of growth hormone/insulin-like growth factors in adipocyte
differentiation. Metabolism 44:4549[CrossRef][Medline]
-
Richelsen B 1997 Action of growth hormone in
adipose tissue. Horm Res 48(Suppl 5):105110
-
Kras KM, Hausman DB, Hausman GJ, Martin RJ 1999 Adipocyte development is dependent upon stem cell recruitment and
proliferation of preadipocytes. Obes Res 7:491497[Medline]
-
Rajkumar K, Modric T, Murphy LJ 1999 Impaired
adipogenesis in insulin-like growth factor binding protein-1 transgenic
mice. J Endocrinol 162:457465[Abstract]
-
Cinti S, Eberbach S, Castellucci M, Accili D 1998 Lack of insulin receptor affects the formation of white adipose tissue
in mice. A morphometric and ultrastructural analysis. Diabetologia 41:171177[CrossRef][Medline]
This article has been cited by other articles:

|
 |

|
 |
 
B. W. Sutherland, S. E. Knoblaugh, P. J. Kaplan-Lefko, F. Wang, M. Holzenberger, and N. M. Greenberg
Conditional Deletion of Insulin-like Growth Factor-I Receptor in Prostate Epithelium
Cancer Res.,
May 1, 2008;
68(9):
3495 - 3504.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Duffield, T. Vuocolo, R. Tellam, B. S. Yuen, B. S. Muhlhausler, and I. C. McMillen
Placental restriction of fetal growth decreases IGF1 and leptin mRNA expression in the perirenal adipose tissue of late gestation fetal sheep
Am J Physiol Regulatory Integrative Comp Physiol,
May 1, 2008;
294(5):
R1413 - R1419.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. B. Hurov, M. Huang, L. S. White, J. Lennerz, C. S. Choi, Y.-R. Cho, H.-J. Kim, J. L. Prior, D. Piwnica-Worms, L. C. Cantley, et al.
Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo
PNAS,
March 27, 2007;
104(13):
5680 - 5685.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Svensson, M Diez, J Engel, C Wass, A Tivesten, J-O Jansson, O Isaksson, T Archer, T Hokfelt, and C Ohlsson
Endocrine, liver-derived IGF-I is of importance for spatial learning and memory in old mice.
J. Endocrinol.,
June 1, 2006;
189(3):
617 - 627.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Raile, J. Klammt, A. Schneider, A. Keller, S. Laue, R. Smith, R. Pfaffle, J. Kratzsch, E. Keller, and W. Kiess
Clinical and Functional Characteristics of the Human Arg59Ter Insulin-Like Growth Factor I Receptor (IGF1R) Mutation: Implications for a Gene Dosage Effect of the Human IGF1R
J. Clin. Endocrinol. Metab.,
June 1, 2006;
91(6):
2264 - 2271.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Sadagurski, S. Yakar, G. Weingarten, M. Holzenberger, C. J. Rhodes, D. Breitkreutz, D. LeRoith, and E. Wertheimer
Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation.
Mol. Cell. Biol.,
April 1, 2006;
26(7):
2675 - 2687.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Svensson, B. Soderpalm, K. Sjogren, J. Engel, and C. Ohlsson
Liver-derived IGF-I regulates exploratory activity in old mice
Am J Physiol Endocrinol Metab,
September 1, 2005;
289(3):
E466 - E473.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X.-J. Du
Gender modulates cardiac phenotype development in genetically modified mice
Cardiovasc Res,
August 15, 2004;
63(3):
510 - 519.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Unger, S. D. Chernausek, W. Kiess, and R. J. Smith
IGF-I Receptor Mutations and Intrauterine and Postnatal Growth Retardation
N. Engl. J. Med.,
March 25, 2004;
350(13):
1362 - 1363.
[Full Text]
|